Celldex Therapeutics Updates Financial Condition in 8-K Filing
Ticker: CLDX · Form: 8-K · Filed: Feb 26, 2024 · CIK: 744218
| Field | Detail |
|---|---|
| Company | Celldex Therapeutics, Inc. (CLDX) |
| Form Type | 8-K |
| Filed Date | Feb 26, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, 8-K, corporate-update
TL;DR
**Celldex Therapeutics just dropped an 8-K on its financials, so keep an eye out for details on their performance.**
AI Summary
Celldex Therapeutics, Inc. filed an 8-K on February 26, 2024, to report on its results of operations and financial condition. The filing indicates that the company, based in Hampton, New Jersey, is providing an update on its financial status. This report is a standard disclosure under the Securities Exchange Act of 1934.
Why It Matters
This filing provides investors with current information on Celldex Therapeutics' financial health and operational performance, which can influence investment decisions and market valuation.
Risk Assessment
Risk Level: low — This is a routine disclosure of financial information, not indicating any immediate adverse events or significant changes.
Key Players & Entities
- Celldex Therapeutics, Inc. (company) — Registrant
- February 26, 2024 (date) — Date of earliest event reported
- Hampton, New Jersey (location) — Business address
- 000-15006 (other) — Commission File Number
- 13-3191702 (other) — I.R.S. Employer Identification No.
FAQ
What is the purpose of this 8-K filing by Celldex Therapeutics, Inc.?
The purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, as well as Financial Statements and Exhibits, as per Item Information.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 26, 2024.
What is the business address of Celldex Therapeutics, Inc.?
The business address of Celldex Therapeutics, Inc. is Perryville III Building, 53 Frontage Road, Suite 220, Hampton, New Jersey 08827.
Under which act is this current report filed?
This current report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the Central Index Key (CIK) for Celldex Therapeutics, Inc.?
The Central Index Key (CIK) for Celldex Therapeutics, Inc. is 0000744218.
Filing Stats: 530 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-02-26 07:01:57
Filing Documents
- f8k_022524.htm (8-K) — 14KB
- exh_991.htm (EX-99.1) — 67KB
- 0001171843-24-000966.txt ( ) — 285KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_022524_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On February 26, 2024, Celldex Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended 2023. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein. The information in this Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release of Celldex Therapeutics, Inc., dated February 26, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Celldex Therapeutics, Inc. Date: February 26, 2024 By: /s/ Sam Martin Sam Martin Senior Vice President and Chief Financial Officer